{"success":true,"data":{"pressRelease":{"id":"35172","rtpr_id":"nGNX1CLrgY","ticker":"GTBP","exchange":"NASDAQ","all_tickers":["GTBP","IDYA","SMMT","RAD"],"title":"A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology","author":"Globe Newswire","published_at":"2026-05-14T13:15:00.169Z","article_body":"Issued on behalf of GT Biopharma, Inc.\n\nFrom bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has\nbecome one of the most actively pursued antigens in solid tumor oncology —\nand a new natural killer cell engager just entered the clinic\n\nSAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group\n(https://www.globenewswire.com/Tracker?data=Ua9MLY40lgltdFLARS6UTgxVsrRZzyvlJzXEJNiK_vr73wGCpnm4_vZ5N_DVKIlX9bVrGAQUVcNB_sAQ3GhvMzKCmNscnbt6OCVkQ0d9cS4=)\nNews Commentary — For more than two decades, B7-H3 sat on the shortlist of\ntheoretically perfect cancer drug targets that nobody could quite figure out\nhow to hit. The protein is broadly overexpressed across some of the most\ncommon — and most lethal — solid tumors, including prostate, lung, breast,\novarian, head and neck, and pancreatic cancers. It is largely absent from\nhealthy tissue. It correlates with poor prognosis. On paper, it has every\nquality a drug developer wants. In practice, three B7-H3-targeting\nantibody-drug conjugates have entered the clinic, and none have yet been\napproved [1].\n\nThat is starting to change.\n\nIn the first half of 2026, a wave of new B7-H3-directed programs from across\nthe U.S. oncology landscape has reached early clinical milestones, ranging\nfrom bispecific antibody-drug conjugates to systemic radiopharmaceuticals to\nnatural killer cell engagers. The mechanisms vary widely. The target does not.\n\nGT Biopharma, Inc. (NASDAQ: GTBP) added itself to that list this week,\nannouncing that the first patient has been dosed in a Phase 1 dose-escalation\nbasket trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager\nfor solid tumors expressing B7-H3 [2]. GTB-5550 is the third TriKE®\n(Tri-specific Killer Engager) molecule from GT Biopharma to enter the clinic\nand the first to be tested with subcutaneous dosing — a notable design\nchoice in a category where most engager therapies have historically required\ncontinuous infusion. The dose-escalation phase will focus primarily on\nprostate cancer, where, according to Dr. Nicholas Zorko of the University of\nMinnesota, B7-H3 is expressed in over 90% of metastatic castration-resistant\ntumors and PSA can serve as an early biomarker of therapeutic activity [2].\n\n\"Dosing the first patient in our GTB-5550 Phase 1 trial is a pivotal milestone\nfor GT Biopharma and represents the natural evolution of our TriKE® platform\ninto the broader opportunity of treating patients with a variety of solid\ntumors,\" said Michael Breen, Executive Chairman and Chief Executive Officer of\nGT Biopharma, in the company's announcement [2]. After dose escalation, the\nPhase 1b expansion will enroll patients across up to seven distinct tumor\ntypes: castration-resistant prostate, ovarian, breast, head and neck,\nnon-small cell lung, pancreatic, and bladder cancer.\n\nStep back from the molecule, though, and the more striking story is the\ncompany GT Biopharma now finds itself in.\n\nBig Pharma Buys In: Summit Therapeutics × GSK\n\nJust four months earlier, Summit Therapeutics Inc. (NASDAQ: SMMT) —\ncurrently one of the largest publicly traded oncology biotechs by market\ncapitalization, with a market value around $14 billion as of early 2026 [3]\n— announced a clinical trial collaboration with GSK plc to evaluate Summit's\nlead bispecific antibody ivonescimab in combination with GSK's novel\ninvestigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan\n(also known as GSK'227), across multiple solid tumor settings, including small\ncell lung cancer [4].\n\nRisvutatug rezetecan is itself a high-profile asset: GSK acquired exclusive\nworldwide rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from\nHansoh Pharma, and GSK's global Phase 3 trial for the drug in relapsed\nextensive-stage small cell lung cancer began in August 2025 [4]. The\ncombination study with Summit is expected to begin dosing patients in\nmid-2026.\n\nThe takeaway for investors watching the antigen is that B7-H3 is no longer an\nacademic curiosity. It is at the center of a deal between one of the\nmost-watched names in U.S. oncology biotech and one of the world's largest\npharmaceutical companies.\n\nPrecision Oncology Gets Bispecific\n\nIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology\ncompany, has taken a different swing at the same antigen. In February 2026,\nIDEAYA announced that the first patient had been enrolled in its Phase 1\ndose-escalation/expansion trial evaluating IDE034, a potential first-in-class\nPTK7/B7-H3 bispecific TOP1 antibody-drug conjugate [5]. The design rationale\nis unusually specific: IDEAYA estimates that B7-H3 and PTK7 are co-expressed\nin approximately 30–40% of certain large solid tumor types — including\nlung, breast, ovarian, and colorectal cancers — while exhibiting minimal\ndual-antigen expression in normal tissue [5]. The drug is designed to be\ninternalized only when both antigens are co-expressed on the same tumor cell,\nan architecture intended to enhance selectivity and tolerability compared to\nmonovalent antibody formats.\n\nIn its first-quarter 2026 update, IDEAYA reaffirmed plans to provide a\nclinical data update for IDE034 by year-end 2026 and confirmed that patient\ndosing in the trial had triggered a $5 million milestone payment to its\ncollaboration partner Biocytogen [6].\n\nBeyond Antibodies: A Radiopharmaceutical Approach\n\nA third U.S.-listed program is testing whether B7-H3 can be hit with radiation\nrather than a payload-conjugated antibody. Radiopharm Theranostics Ltd.\n(NASDAQ: RADX), through its Radiopharm Ventures joint venture with The\nUniversity of Texas MD Anderson Cancer Center, is advancing 177Lu-BetaBart\n(RV-01), a Lutetium-177-tagged engineered monoclonal antibody designed with\nstrong affinity for the 4Ig isoform of B7-H3 — the first clinical trial\nglobally to target B7-H3 with a systemic radiopharmaceutical [7]. Radiopharm\ndosed the first patient in the First-In-Human Phase 1/2a clinical trial of\n177Lu-BetaBart on February 24, 2026 [8]. The trial follows FDA IND clearance\nreceived in July 2025, and in January 2026 Radiopharm announced it had\nincreased its ownership stake in Radiopharm Ventures to 87.5%, deepening its\nexposure to the BetaBart program [7].\n\nTaken together — antibody-drug conjugates, bispecific ADCs, systemic\nradiopharmaceuticals, natural killer cell engagers — B7-H3 is now being\nattacked from four distinct therapeutic angles across at least four publicly\ntraded U.S. companies in 2026 alone.\n\nWhy Subcutaneous Matters in This Wave\n\nAmong that group, GT Biopharma's GTB-5550 stands out for two structural\nreasons. First, the engager is the only one of the named programs that relies\non natural killer cells rather than T cells, antibody payloads, or radiation.\nNK cells are part of the innate immune system, act faster than T cells, do not\nrequire MHC presentation, and have historically been associated with lower\nrates of cytokine release syndrome — features that have made them a focus of\nan entire emerging therapeutic category. Second, GTB-5550 is being\nadministered subcutaneously, in the abdominal area, for five consecutive days\nduring Week 1 and Week 2 of each four-week cycle [2]. Subsequent cycles are\ndosed three times weekly for two weeks followed by two weeks of no treatment.\n\nThe implication for patients — and for the eventual commercial logistics of\nany approved therapy — is that treatment may not require an infusion center.\n\nA Pipeline-Defining Year\n\nGT Biopharma has indicated that it expects to provide updates on the GTB-5550\ntrial throughout the second half of 2026 as enrollment progresses through the\ndose-escalation cohorts [2]. Patients are followed for 12 months to determine\nprogression-free survival and overall survival. The trial is registered under\nclinicaltrials.gov identifier NCT07541573 [2].\n\nIn a category that took two decades to get its first programs into the clinic,\nthe pace of activity in 2026 alone is striking. From a small-cap NK cell\nengager developer to a mega-cap bispecific antibody company partnering with\nGSK, B7-H3 is no longer the target that pharma circled and walked away from.\nIt is the target everyone is racing to crack — and the patient just dosed in\nSan Francisco this week is one more data point in that race.\n\nContinuing coverage of GT Biopharma, Inc. and the broader B7-H3 oncology\nlandscape is available at gtbiopharma.com\n(https://www.globenewswire.com/Tracker?data=ICi601vY3LPNuAR0mMmzsoHyaNiSBm3mS89Po52NnW0zNwGa7ZinQl4j7M1esrY79iIMJgCNIZWGJTG5zP5yqHDZ9HBQ1kpbKy2mLjF-_Jw=).\n\nContact\n\nUSA News Group\ninfo@usanewsgroup.com\n604-265-2873\n\nArticle Sources\n\n1. ITC-6102RO research — B7-H3 ADC clinical development overview, National\nCenter for Biotechnology Information —\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439577/\n\n2. GT Biopharma, Inc. — GT Biopharma Announces First Patient Dosed in Phase\n1 Trial of GTB-5550 (May 14, 2026) —\nhttps://www.globenewswire.com/NewsRoom/ReleaseNg/7602764 \n\n3. Summit Therapeutics (SMMT) Market Capitalization — Public.com /\nStockAnalysis — https://stockanalysis.com/stocks/smmt/market-cap/\n\n4. Summit Therapeutics Inc. — Summit Therapeutics Announces Clinical Trial\nCollaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3\nAntibody Drug Conjugate (ADC) (January 12, 2026) —\nhttps://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-Clinical-Trial-Collaboration-with-GSK-to-Evaluate-Ivonescimab-in-Combination-with-GSKs-B7-H3-Antibody-Drug-Conjugate-ADC/default.aspx\n\n5. IDEAYA Biosciences, Inc. — IDEAYA Biosciences Announces First-Patient-In\nfor Phase 1 Trial of IDE034 (February 25, 2026) —\nhttps://ir.ideayabio.com/2026-02-25-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE034,-a-Potential-First-In-Class-B7H3-PTK7-Bispecific-TOP1-ADC\n\n6. IDEAYA Biosciences, Inc. — Q1 2026 Financial Results and Business Update\n—\nhttps://www.sec.gov/Archives/edgar/data/0001676725/000119312526204944/idya-ex99_1.htm\n\n7. Radiopharm Theranostics Ltd. — RAD Increases Ownership in Radiopharm\nVentures to 87.5% (January 12, 2026) —\nhttps://www.sec.gov/Archives/edgar/data/0001949257/000121390026003148/ea027252001ex99-1_radiopharm.htm\n\n8. Radiopharm Theranostics Ltd. — Radiopharm Theranostics Doses First\nPatient in Phase 1/2a Clinical Study of BetaBart (RV-01) (February 24, 2026)\n—\nhttps://www.globenewswire.com/news-release/2026/02/24/3243439/0/en/Radiopharm-Theranostics-Doses-First-Patient-in-Phase-1-2a-Clinical-Study-of-BetaBart-RV-01.html\n\nDISCLAIMER:\n\nNothing in this publication should be considered as personalized financial\nadvice. We are not licensed under securities laws to address your particular\nfinancial situation. No communication by our employees to you should be deemed\nas personalized financial advice. Please consult a licensed financial advisor\nbefore making any investment decision. This is a paid advertisement and is\nneither an offer nor recommendation to buy or sell any security. We hold no\ninvestment licenses and are thus neither licensed nor qualified to provide\ninvestment advice. The content in this report or email is not provided to any\nindividual with a view toward their individual circumstances. USA News Group\nis a wholly-owned subsidiary of Market IQ Media Group, Inc. (\"MIQ\"). MIQ has\nbeen paid a fee for GT Biopharma, Inc. advertising and digital media from\nCreative Digital Media Group (\"CDMG\"). There may be 3rd parties who may have\nshares of GT Biopharma, Inc., and may liquidate their shares which could have\na negative effect on the price of the stock. This compensation constitutes a\nconflict of interest as to our ability to remain objective in our\ncommunication regarding the profiled company. Because of this conflict,\nindividuals are strongly encouraged to not use this article as the basis for\nany investment decision. The owner/operator of MIQ does not own any shares of\nGT Biopharma, Inc. and reserves the right to buy and sell, and will buy and\nsell shares of GT Biopharma, Inc. at any time without any further notice\ncommencing immediately and ongoing. This article and content is not, and\nshould not be, considered or relied upon as financial advice. Reproduction\nwithout explicit permission is prohibited. If you are looking for further\ninformation regarding this advertisement, please review the contents on the\ndisclaimer page of the website which displayed this advertisement. By visiting\nand/or otherwise using the USA News Group website in any way, you indicate\nthat you understand and accept the terms of use as set forth on the website\nand agree to be bound by them. If you do not agree to the website's terms of\nuse, please do not access the website or any pages thereof. Any email\naddresses provided will never be shared with any 3rd party. This release was\nreviewed and approved on behalf of GT Biopharma, Inc. by Creative Digital\nMedia Group (\"CDMG\"). Forward-looking statements within the meaning of Section\n27A of the Securities Act of 1933 and Section 21E of the Securities Exchange\nAct of 1934 included in this publication are subject to risks and\nuncertainties that could cause actual results to differ materially from those\nprojected. Readers are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2f54e5ac-913c-4cd9-b83b-5ebd616705c2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1CLrgY","title":"A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology","author":"Globe Newswire","ticker":"GTBP","created":"2026-05-14T13:15:00.169Z","tickers":["GTBP","IDYA","SMMT","RAD"],"exchange":"NASDAQ","article_body":"Issued on behalf of GT Biopharma, Inc.\n\nFrom bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has\nbecome one of the most actively pursued antigens in solid tumor oncology —\nand a new natural killer cell engager just entered the clinic\n\nSAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group\n(https://www.globenewswire.com/Tracker?data=Ua9MLY40lgltdFLARS6UTgxVsrRZzyvlJzXEJNiK_vr73wGCpnm4_vZ5N_DVKIlX9bVrGAQUVcNB_sAQ3GhvMzKCmNscnbt6OCVkQ0d9cS4=)\nNews Commentary — For more than two decades, B7-H3 sat on the shortlist of\ntheoretically perfect cancer drug targets that nobody could quite figure out\nhow to hit. The protein is broadly overexpressed across some of the most\ncommon — and most lethal — solid tumors, including prostate, lung, breast,\novarian, head and neck, and pancreatic cancers. It is largely absent from\nhealthy tissue. It correlates with poor prognosis. On paper, it has every\nquality a drug developer wants. In practice, three B7-H3-targeting\nantibody-drug conjugates have entered the clinic, and none have yet been\napproved [1].\n\nThat is starting to change.\n\nIn the first half of 2026, a wave of new B7-H3-directed programs from across\nthe U.S. oncology landscape has reached early clinical milestones, ranging\nfrom bispecific antibody-drug conjugates to systemic radiopharmaceuticals to\nnatural killer cell engagers. The mechanisms vary widely. The target does not.\n\nGT Biopharma, Inc. (NASDAQ: GTBP) added itself to that list this week,\nannouncing that the first patient has been dosed in a Phase 1 dose-escalation\nbasket trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager\nfor solid tumors expressing B7-H3 [2]. GTB-5550 is the third TriKE®\n(Tri-specific Killer Engager) molecule from GT Biopharma to enter the clinic\nand the first to be tested with subcutaneous dosing — a notable design\nchoice in a category where most engager therapies have historically required\ncontinuous infusion. The dose-escalation phase will focus primarily on\nprostate cancer, where, according to Dr. Nicholas Zorko of the University of\nMinnesota, B7-H3 is expressed in over 90% of metastatic castration-resistant\ntumors and PSA can serve as an early biomarker of therapeutic activity [2].\n\n\"Dosing the first patient in our GTB-5550 Phase 1 trial is a pivotal milestone\nfor GT Biopharma and represents the natural evolution of our TriKE® platform\ninto the broader opportunity of treating patients with a variety of solid\ntumors,\" said Michael Breen, Executive Chairman and Chief Executive Officer of\nGT Biopharma, in the company's announcement [2]. After dose escalation, the\nPhase 1b expansion will enroll patients across up to seven distinct tumor\ntypes: castration-resistant prostate, ovarian, breast, head and neck,\nnon-small cell lung, pancreatic, and bladder cancer.\n\nStep back from the molecule, though, and the more striking story is the\ncompany GT Biopharma now finds itself in.\n\nBig Pharma Buys In: Summit Therapeutics × GSK\n\nJust four months earlier, Summit Therapeutics Inc. (NASDAQ: SMMT) —\ncurrently one of the largest publicly traded oncology biotechs by market\ncapitalization, with a market value around $14 billion as of early 2026 [3]\n— announced a clinical trial collaboration with GSK plc to evaluate Summit's\nlead bispecific antibody ivonescimab in combination with GSK's novel\ninvestigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan\n(also known as GSK'227), across multiple solid tumor settings, including small\ncell lung cancer [4].\n\nRisvutatug rezetecan is itself a high-profile asset: GSK acquired exclusive\nworldwide rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from\nHansoh Pharma, and GSK's global Phase 3 trial for the drug in relapsed\nextensive-stage small cell lung cancer began in August 2025 [4]. The\ncombination study with Summit is expected to begin dosing patients in\nmid-2026.\n\nThe takeaway for investors watching the antigen is that B7-H3 is no longer an\nacademic curiosity. It is at the center of a deal between one of the\nmost-watched names in U.S. oncology biotech and one of the world's largest\npharmaceutical companies.\n\nPrecision Oncology Gets Bispecific\n\nIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology\ncompany, has taken a different swing at the same antigen. In February 2026,\nIDEAYA announced that the first patient had been enrolled in its Phase 1\ndose-escalation/expansion trial evaluating IDE034, a potential first-in-class\nPTK7/B7-H3 bispecific TOP1 antibody-drug conjugate [5]. The design rationale\nis unusually specific: IDEAYA estimates that B7-H3 and PTK7 are co-expressed\nin approximately 30–40% of certain large solid tumor types — including\nlung, breast, ovarian, and colorectal cancers — while exhibiting minimal\ndual-antigen expression in normal tissue [5]. The drug is designed to be\ninternalized only when both antigens are co-expressed on the same tumor cell,\nan architecture intended to enhance selectivity and tolerability compared to\nmonovalent antibody formats.\n\nIn its first-quarter 2026 update, IDEAYA reaffirmed plans to provide a\nclinical data update for IDE034 by year-end 2026 and confirmed that patient\ndosing in the trial had triggered a $5 million milestone payment to its\ncollaboration partner Biocytogen [6].\n\nBeyond Antibodies: A Radiopharmaceutical Approach\n\nA third U.S.-listed program is testing whether B7-H3 can be hit with radiation\nrather than a payload-conjugated antibody. Radiopharm Theranostics Ltd.\n(NASDAQ: RADX), through its Radiopharm Ventures joint venture with The\nUniversity of Texas MD Anderson Cancer Center, is advancing 177Lu-BetaBart\n(RV-01), a Lutetium-177-tagged engineered monoclonal antibody designed with\nstrong affinity for the 4Ig isoform of B7-H3 — the first clinical trial\nglobally to target B7-H3 with a systemic radiopharmaceutical [7]. Radiopharm\ndosed the first patient in the First-In-Human Phase 1/2a clinical trial of\n177Lu-BetaBart on February 24, 2026 [8]. The trial follows FDA IND clearance\nreceived in July 2025, and in January 2026 Radiopharm announced it had\nincreased its ownership stake in Radiopharm Ventures to 87.5%, deepening its\nexposure to the BetaBart program [7].\n\nTaken together — antibody-drug conjugates, bispecific ADCs, systemic\nradiopharmaceuticals, natural killer cell engagers — B7-H3 is now being\nattacked from four distinct therapeutic angles across at least four publicly\ntraded U.S. companies in 2026 alone.\n\nWhy Subcutaneous Matters in This Wave\n\nAmong that group, GT Biopharma's GTB-5550 stands out for two structural\nreasons. First, the engager is the only one of the named programs that relies\non natural killer cells rather than T cells, antibody payloads, or radiation.\nNK cells are part of the innate immune system, act faster than T cells, do not\nrequire MHC presentation, and have historically been associated with lower\nrates of cytokine release syndrome — features that have made them a focus of\nan entire emerging therapeutic category. Second, GTB-5550 is being\nadministered subcutaneously, in the abdominal area, for five consecutive days\nduring Week 1 and Week 2 of each four-week cycle [2]. Subsequent cycles are\ndosed three times weekly for two weeks followed by two weeks of no treatment.\n\nThe implication for patients — and for the eventual commercial logistics of\nany approved therapy — is that treatment may not require an infusion center.\n\nA Pipeline-Defining Year\n\nGT Biopharma has indicated that it expects to provide updates on the GTB-5550\ntrial throughout the second half of 2026 as enrollment progresses through the\ndose-escalation cohorts [2]. Patients are followed for 12 months to determine\nprogression-free survival and overall survival. The trial is registered under\nclinicaltrials.gov identifier NCT07541573 [2].\n\nIn a category that took two decades to get its first programs into the clinic,\nthe pace of activity in 2026 alone is striking. From a small-cap NK cell\nengager developer to a mega-cap bispecific antibody company partnering with\nGSK, B7-H3 is no longer the target that pharma circled and walked away from.\nIt is the target everyone is racing to crack — and the patient just dosed in\nSan Francisco this week is one more data point in that race.\n\nContinuing coverage of GT Biopharma, Inc. and the broader B7-H3 oncology\nlandscape is available at gtbiopharma.com\n(https://www.globenewswire.com/Tracker?data=ICi601vY3LPNuAR0mMmzsoHyaNiSBm3mS89Po52NnW0zNwGa7ZinQl4j7M1esrY79iIMJgCNIZWGJTG5zP5yqHDZ9HBQ1kpbKy2mLjF-_Jw=).\n\nContact\n\nUSA News Group\ninfo@usanewsgroup.com\n604-265-2873\n\nArticle Sources\n\n1. ITC-6102RO research — B7-H3 ADC clinical development overview, National\nCenter for Biotechnology Information —\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439577/\n\n2. GT Biopharma, Inc. — GT Biopharma Announces First Patient Dosed in Phase\n1 Trial of GTB-5550 (May 14, 2026) —\nhttps://www.globenewswire.com/NewsRoom/ReleaseNg/7602764 \n\n3. Summit Therapeutics (SMMT) Market Capitalization — Public.com /\nStockAnalysis — https://stockanalysis.com/stocks/smmt/market-cap/\n\n4. Summit Therapeutics Inc. — Summit Therapeutics Announces Clinical Trial\nCollaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3\nAntibody Drug Conjugate (ADC) (January 12, 2026) —\nhttps://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-Clinical-Trial-Collaboration-with-GSK-to-Evaluate-Ivonescimab-in-Combination-with-GSKs-B7-H3-Antibody-Drug-Conjugate-ADC/default.aspx\n\n5. IDEAYA Biosciences, Inc. — IDEAYA Biosciences Announces First-Patient-In\nfor Phase 1 Trial of IDE034 (February 25, 2026) —\nhttps://ir.ideayabio.com/2026-02-25-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE034,-a-Potential-First-In-Class-B7H3-PTK7-Bispecific-TOP1-ADC\n\n6. IDEAYA Biosciences, Inc. — Q1 2026 Financial Results and Business Update\n—\nhttps://www.sec.gov/Archives/edgar/data/0001676725/000119312526204944/idya-ex99_1.htm\n\n7. Radiopharm Theranostics Ltd. — RAD Increases Ownership in Radiopharm\nVentures to 87.5% (January 12, 2026) —\nhttps://www.sec.gov/Archives/edgar/data/0001949257/000121390026003148/ea027252001ex99-1_radiopharm.htm\n\n8. Radiopharm Theranostics Ltd. — Radiopharm Theranostics Doses First\nPatient in Phase 1/2a Clinical Study of BetaBart (RV-01) (February 24, 2026)\n—\nhttps://www.globenewswire.com/news-release/2026/02/24/3243439/0/en/Radiopharm-Theranostics-Doses-First-Patient-in-Phase-1-2a-Clinical-Study-of-BetaBart-RV-01.html\n\nDISCLAIMER:\n\nNothing in this publication should be considered as personalized financial\nadvice. We are not licensed under securities laws to address your particular\nfinancial situation. No communication by our employees to you should be deemed\nas personalized financial advice. Please consult a licensed financial advisor\nbefore making any investment decision. This is a paid advertisement and is\nneither an offer nor recommendation to buy or sell any security. We hold no\ninvestment licenses and are thus neither licensed nor qualified to provide\ninvestment advice. The content in this report or email is not provided to any\nindividual with a view toward their individual circumstances. USA News Group\nis a wholly-owned subsidiary of Market IQ Media Group, Inc. (\"MIQ\"). MIQ has\nbeen paid a fee for GT Biopharma, Inc. advertising and digital media from\nCreative Digital Media Group (\"CDMG\"). There may be 3rd parties who may have\nshares of GT Biopharma, Inc., and may liquidate their shares which could have\na negative effect on the price of the stock. This compensation constitutes a\nconflict of interest as to our ability to remain objective in our\ncommunication regarding the profiled company. Because of this conflict,\nindividuals are strongly encouraged to not use this article as the basis for\nany investment decision. The owner/operator of MIQ does not own any shares of\nGT Biopharma, Inc. and reserves the right to buy and sell, and will buy and\nsell shares of GT Biopharma, Inc. at any time without any further notice\ncommencing immediately and ongoing. This article and content is not, and\nshould not be, considered or relied upon as financial advice. Reproduction\nwithout explicit permission is prohibited. If you are looking for further\ninformation regarding this advertisement, please review the contents on the\ndisclaimer page of the website which displayed this advertisement. By visiting\nand/or otherwise using the USA News Group website in any way, you indicate\nthat you understand and accept the terms of use as set forth on the website\nand agree to be bound by them. If you do not agree to the website's terms of\nuse, please do not access the website or any pages thereof. Any email\naddresses provided will never be shared with any 3rd party. This release was\nreviewed and approved on behalf of GT Biopharma, Inc. by Creative Digital\nMedia Group (\"CDMG\"). Forward-looking statements within the meaning of Section\n27A of the Securities Act of 1933 and Section 21E of the Securities Exchange\nAct of 1934 included in this publication are subject to risks and\nuncertainties that could cause actual results to differ materially from those\nprojected. Readers are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2f54e5ac-913c-4cd9-b83b-5ebd616705c2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-14T13:15:00.236387608Z","server_sent_at_ms":1778764500236},"received_at":"2026-05-14T13:15:00.366Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}